Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Debt to Equity: 2010-2025

Historic Debt to Equity for Arrowhead Pharmaceuticals (ARWR) over the last 9 years, with Sep 2025 value amounting to $0.51.

  • Arrowhead Pharmaceuticals' Debt to Equity fell 75.40% to $0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.51, marking a year-over-year decrease of 75.40%. This contributed to the annual value of $0.51 for FY2025, which is 75.40% down from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Debt to Equity stood at $0.51, which was up 10.04% from $0.46 recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Debt to Equity high stood at $7.30 for Q4 2024, and its period low was $0.40 during Q1 2025.
  • In the last 2 years, Arrowhead Pharmaceuticals' Debt to Equity had a median value of $0.51 in 2025 and averaged $2.15.
  • Data for Arrowhead Pharmaceuticals' Debt to Equity shows a maximum YoY slumped of 75.40% (in 2025) over the last 5 years.
  • Arrowhead Pharmaceuticals' Debt to Equity (Quarterly) stood at $7.30 in 2024, then slumped by 75.40% to $0.51 in 2025.
  • Its last three reported values are $0.51 in Q3 2025, $0.46 for Q2 2025, and $0.40 during Q1 2025.